Kits for nerve treatment methods

Abstract

The present disclosure is directed to kits comprising materials appropriate for treating damaged nerves, such as for reconnecting severed nerves, through the use of fusogenic compounds such as polyethylene glycol (PEG) in combination with antioxidants, calcium-containing and calcium-free solutions.

1 .- 22 . (canceled) 
     
     
         23 . A kit for use in a pharmaceutical agent delivery sequence, comprising at least one lipid membrane fusogen; instructions indicating that the pharmaceutical agent delivery sequence includes at least one of the antioxidant inhibitor of membrane sealing followed by the at least one lipid membrane fusogen; and optionally including an antioxidant inhibitor of membrane sealing. 
     
     
         24 . The kit of  claim 23 , wherein the kit comprises at least one lipid membrane fusogen. 
     
     
         25 . The kit of  claim 23 , further comprising a calcium-containing saline solution. 
     
     
         26 . The kit of  claim 23 , further comprising a hypotonic, calcium-free saline solution. 
     
     
         27 . The kit of  claim 26 , wherein the hypotonic calcium-free saline solution comprises sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, sodium bicarbonate, sodium ascorbate, and/or dextrose. 
     
     
         28 . The kit of  claim 23 , wherein said lipid membrane fusogen comprises polyethylene glycol (PEG). 
     
     
         29 . The kit of  claim 28 , wherein the PEG is present at a concentration of from 100 to 500 mM. 
     
     
         30 . The kit of  claim 23 , wherein one or more of the solutions are contained within syringes. 
     
     
         31 . The kit of  claim 23 , wherein reagents of the kit are comprised in separate barrels of a double-barreled syringe. 
     
     
         32 . The kit of  claim 23 , wherein the optional antioxidant is methylene blue. 
     
     
         33 . The kit of  claim 23 , wherein the optional antioxidant is melatonin.